Commercial success in precision medicine: Six watchouts and best practices for pharma

Diagnostics barriers keep many patients from benefiting from targeted therapies. Discover six key watchouts and how pharma can improve test access and unlock the full value of precision medicine.

Precision medicine is a top priority for many pharmaceutical companies, driven by its potential to deliver highly targeted therapies that improve patient outcomes. Data shows that it now accounts for over one-third of FDA drug approvals, with the number of new FDA-approved biomarkers doubling every five years. Commercial success, however, depends on more than the ability to identify biomarker-positive patient population. It requires guiding them through the diagnostic journey, which involves four key steps:

• Awareness of biomarker test timing and purpose: Physicians understand the need for biomarker testing and how the targeted therapy is a potential treatment option.
• Test ordering: Physicians obtain the…